Drug intelligence / Profile preview

VirDUB

Development stage: Preclinical
Lead developer: WEHI
Modality: Small Molecules

Overview

VirDUB is a preclinical small-molecule inhibitor developed by the Walter and Eliza Hall Institute (WEHI) in collaboration with Roche. It specifically targets the papain-like protease (PLPro) of the SARS-CoV-2 virus. PLPro is a critical enzyme for viral replication and also plays a role in evading the host's immune response by acting as a deubiquitinating (DUB) enzyme, removing ubiquitin and ISG15 from host proteins. By inhibiting PLPro, VirDUB aims to block viral replication and restore the host's innate immune signaling. The drug is being investigated for the treatment of COVID-19 and potentially Long COVID.

Other names: VirDUB – targeting PLPro

Targets

PLpro (Papain-like protease)

Beyond the preview

Go deeper on VirDUB.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VirDUB.

Explore the full profile